Navigation Links
InfoGroup Founder and Board Member Criticizes Adoption of Poison Pill

Board Should Pursue Strategic Alternatives Rather than Seek to Entrench Itself

OMAHA, Neb., May 18 /PRNewswire/ -- Vinod Gupta, the founder, member of the board of directors and holder of approximately 39% of the outstanding stock of InfoGroup (Nasdaq: IUSA) announced today that he strongly disagreed with the Company's recent decision to adopt a poison pill and believes that the Company must explore strategic alternatives.

"I believe that the Board of Directors' adoption of a 'poison pill' demonstrates that many of the directors are willing to entrench themselves at the expense of the Company's stockholders," said Mr. Gupta. "Unfortunately, this conduct is consistent with past Board actions. When I entered into a settlement agreement with the Company in 2008, the Board insisted that I vote all my shares in favor of the Board's nominees for director rather than proportionately with the shares of the Company's unaffiliated stockholders, as I had strongly demanded. The Board simply wanted to control my votes (approximately 39% of the Company's voting stock) to assure that they could keep their board seats rather than give the stockholders, to whom they should owe their allegiance, a meaningful say in the election of directors," Mr. Gupta stated.

"I regret that some members of this Board, who do not own a meaningful amount of stock in the Company like I do, seem much more interested in assuring that they retain their directorships than in doing what is best for the stockholders of the Company. I sincerely hope that all stockholders, as well as Risk Metrics, let these members of the Board know their displeasure with the Board's decision to adopt a rights plan," Mr. Gupta continued.

"It is bad enough that a majority of the Board would take this action against the best interests of all of the stockholders. However, in my case, their conduct amounts to a breach by the Board of an agreement between the Company and me, as described in the letter to the Board attached to this press release," said Mr. Gupta.

"Even the adoption of the poison pill might not be so bad in isolation. But the poison pill has to be judged against the background of the Company's dismal performance since new management was installed and other actions by a majority of the Board to feather the nest of directors and senior management. These include:

  • The Company's revenues in the March 2009 quarter declined 17% and operating income declined 34% from the first quarter of last year.
  • These results are much worse than the Company's peer group: in the March 2009 quarter, Dun & Bradstreet's revenues only declined 2% and its operating income actually increased 5% from the first quarter of last year.
  • The Board has discontinued the Company's annual dividend, depriving the stockholders of last year's dividend of $0.35 per share.
  • This dismal performance hasn't stopped the Board from treating itself and management quite well.
    • Four of the directors received directors fees of approximately $296,000, $288,000, $273,000 and $248,000, respectively, in 2008. This is a total of directors fees of approximately $1,105,000 for just these four directors.
    • The Board gave away more than 900,000 shares of restricted stock to senior management.
    • The Board gave change of control benefits for the four top officers that could total approximately $9,400,000.
    • The Board provided a compensation package to its new CEO, who has no experience in the industry, which contemplates $1,500,000 annual cash compensation as well as discretionary equity compensation. In 2008, the fair value of the CEO's discretionary equity compensation was $726,000, such that his total 2008 compensation was $2,226,000.

Mr. Gupta said.

"I strongly believe that it is in the best interests of the stockholders for the Board to explore the Company's strategic alternatives rather than for the Board to seek to entrench itself and waste money on the Board and the Company's top executives. In my capacity as a stockholder of the Company, I have been approached by both strategic and financial buyers about potential transactions but I believe the Company has failed to engage with them in any meaningful way. I remain open to a sale of the Company and would be willing to participate (or not participate) with the buyer if that helped get a transaction done," Mr. Gupta concluded.

SOURCE Vinod Gupta
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
2. Center for Health Transformation Founder Newt Gingrich Calls on Congress to Pass a Clean SCHIP Six-Month Extension
3. Forbes Honors Susan G. Komen for the Cure Founder as Trailblazer
4. Cardinal Health Names CEO R. Kerry Clark as Chairman; Company Founder Robert D. Walter to Retire After 36 Years
5. Susan G. Komen for the Cure Founder Sworn in as Chief of Protocol
6. FalconStor Software Inc. Founders Make Multi-Million Dollar Donation to North Shore-LIJ Health System for Asian Community Health Center in Flushing
7. GeoVax Co-Founder Dr. Harriet Robinson Named 2007 AAAS Fellow
8. Former NFL Star Tiki Barber and CURE Founder Susan Axelrod Speak Out About Epilepsy on TODAY Show
9. Lenny Dykstra, Founder & President of The Players Club, to Keynote the 2008 Financial Communications Forum
10. Intel Co-Founder Andrew S. Grove Dedicates Portion of His Estate, Up to $40 Million, to Michael J. Fox Foundation
11. Childrens Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis
Post Your Comments:
(Date:11/25/2015)... ... ... Many people know of the common symptoms of low thyroid hormone (also known ... people who find their cholesterol levels and weight are creeping up are more likely ... don’t have any of the other symptoms. , Thyroid hormone plays a major role ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis ... Care Plan software creates an agreement between the practice owner and the patient ... scheduling, monitoring, notification, and projections. Click here to learn more. ...
(Date:11/24/2015)... ... , ... Charitable giving is at its peak during the holidays. In ... of the year totalling over $358 billion in 2014. With more than 1.5 ... those individuals who want to “give back” during the holidays. , “With so many ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... national leaders when it comes to several aspects of orthopedic care. They have ... replacements, orthopedic surgeries and general orthopedic care. , Becker's Hospital Review selected ...
(Date:11/24/2015)... Port Richey, FL (PRWEB) , ... November 24, 2015 , ... ... it deems a growing epidemic as deaths from prescription opioids in the United States ... heroin and cocaine. In 2013 alone, opioids were involved in 37 percent of all ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 25, 2015 WuXi PharmaTech (Cayman) Inc. ("WuXi" ... open-access R&D capability and technology platform company serving the ... China and the ... extraordinary general meeting of shareholders held today, the Company,s ... and approve the previously announced agreement and plan of ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  In the ... projects in an effort to quickly uncover new insights, ... --> --> However, ... a market research project and ensure that all rules ... and industry standards. Another major barrier to efficiently launching ...
(Date:11/24/2015)... Va. , Nov. 24, 2015  DILON Diagnostics ... have signed an agreement for DILON to distribute GE,s ... across the globe. The signing of this distribution agreement will ... NM750b Molecular Breast Imaging system and is considered an ... provide better healthcare solutions for clinicians and their patients. ...
Breaking Medicine Technology: